Aarti Drugs Limited (ADL) is a significant Indian pharmaceutical company, part of the esteemed Aarti Group of Industries. Established in 1984, ADL has emerged as a leading manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company boasts a strong global presence, exporting its products to over 100 countries worldwide. ADL is deeply committed to research and development to maintain its competitive edge, focusing on quality, affordability, and sustainability in healthcare. Their diverse product portfolio addresses various therapeutic segments, making them a key player in the global pharmaceutical market.
The Mumbai headquarters serves as the central command for corporate strategy, financial management, global sales and marketing initiatives, regulatory affairs, human resources, and overall administrative functions for Aarti Drugs Limited.
The headquarters is situated within the Mahendra Industrial Estate, offering strategic access to Mumbai's business ecosystem and logistical networks. It features modern corporate office facilities designed to support its administrative and strategic operations.
Aarti Drugs fosters a professional, quality-focused, and results-driven work culture typical of the pharmaceutical sector. Emphasis is placed on compliance with stringent industry standards, innovation, continuous learning, and collaborative teamwork to achieve business objectives.
The Mumbai headquarters is pivotal due to its location in India's financial capital, which facilitates national and international business dealings, access to a skilled talent pool, and proximity to key regulatory bodies and financial institutions.
Aarti Drugs Limited has established a robust global presence, exporting its wide range of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals to over 100 countries. Key markets include regions in Asia, Europe, Latin America, Africa, and North America. This global outreach is supported by a strong distribution network, consistent adherence to international quality standards (including certifications like USFDA, EU GMP, WHO GMP, KFDA), and active participation in global pharmaceutical trade shows and collaborations. Functions supported globally encompass international sales and marketing, global supply chain management, customer relationship management, and ensuring regulatory compliance for diverse international markets.
Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East)
Mumbai
Maharashtra
India
Address: Plot No. N-198, M.I.D.C., Tarapur, Boisar, Dist. Palghar - 401506, Maharashtra, India (Example of one of their Tarapur units)
Serves as a major production hub in Western India, leveraging the industrial infrastructure of the Tarapur MIDC (Maharashtra Industrial Development Corporation) area. It supports both domestic and international market demands.
Address: Plot No. 901/1, 901/2, 902, GIDC, Sarigam – 396155, Dist. Valsad, Gujarat, India (Example of one of their Sarigam units)
Strategically located in the chemical industrial belt of Gujarat, benefiting from a robust industrial ecosystem, skilled labor, and port connectivity for efficient raw material sourcing and product export.
Address: Aarti Research & Technology Centre, Plot No. D-300, TTC Industrial Area, MIDC-Turbhe, Navi Mumbai - 400705, Maharashtra, India
Drives the company's long-term growth and competitiveness by fostering innovation and technological advancement in pharmaceutical sciences. Its location in Navi Mumbai provides access to a skilled scientific community and research infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aarti Drugs Limited' leadership includes:
Aarti Drugs Limited has been backed by several prominent investors over the years, including:
In the past 12 months, Aarti Drugs Limited has experienced key transitions in its leadership, notably involving the Company Secretary & Compliance Officer role and the retirement of a Whole-Time Director. These changes are part of the company's standard corporate governance and succession planning processes.
Discover the tools Aarti Drugs Limited uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aarti Drugs Limited, like many corporations, likely utilizes standardized email formats for its employees. While the exact formats can vary, common structures involve combinations of employee names and the company domain 'aartidrugs.com'. Understanding these patterns can be useful for professional communication.
Common email formats for Aarti Drugs Limited include `[first].[last]@aartidrugs.com` (e.g., jane.doe@aartidrugs.com) and `[first_initial][last]@aartidrugs.com` (e.g., jdoe@aartidrugs.com). The format `[first]@aartidrugs.com` (e.g. jane@aartidrugs.com) might also be used for some employees.
Format
prakash.patil@aartidrugs.com
Example
75%
Success rate
Business Standard • May 30, 2024
Aarti Drugs reported a 19.3% year-on-year decline in its consolidated net profit to Rs 56.50 crore for the quarter ended March 31, 2024. Revenue from operations also saw a decrease to Rs 662.09 crore from Rs 696.47 crore in the corresponding quarter of the previous year. The company cited challenging market conditions and pressure on input costs as factors impacting performance....more
Moneycontrol • February 14, 2024
Aarti Drugs Ltd reported an 18.6 percent year-on-year (YoY) fall in consolidated profit after tax (PAT) at Rs 50.2 crore for the quarter ended December 2023. Consolidated net sales for the quarter stood at Rs 636.05 crore, down 4.15 percent YoY....more
BSE India (Corporate Announcement) • November 11, 2023
Aarti Drugs Limited informed the stock exchanges about the appointment of Ms. Snehal K. Kauthankar as the Company Secretary and Compliance Officer of the company, effective from November 11, 2023. This followed the resignation of Mr. Ajinkya S. Kulkarni from the said post....more
CARE Ratings • January 18, 2024
CARE Ratings reaffirmed the credit ratings for Aarti Drugs Limited's bank facilities. The long-term bank facilities were reaffirmed at CARE AA-; Stable, and short-term bank facilities at CARE A1+. The ratings continue to derive strength from the company's established market position, diversified product portfolio, and experienced management....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aarti Drugs Limited, are just a search away.